Medexus Returns Gleolan U.S. Rights to NX Development Corp.

Medexus Pharmaceuticals Inc ( (TSE:MDP) ) has provided an announcement.

Medexus Pharmaceuticals has finalized an agreement with NX Development Corp. to return the U.S. commercialization rights for Gleolan, a move that will see NXDC assume responsibility for the product by March 31, 2025. This strategic decision allows Medexus to receive a per-unit payment on Gleolan sales through June 2025, aligning with the company’s interests and ensuring continued availability of the product for patients, while potentially reducing royalty obligations.

More about Medexus Pharmaceuticals Inc

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. The company focuses on therapeutic areas such as hematology-oncology, allergy, dermatology, and rheumatology.

YTD Price Performance: -25.51%

Average Trading Volume: 125,084

Technical Sentiment Consensus Rating: Buy

Current Market Cap: C$83.4M

For detailed information about MDP stock, go to TipRanks’ Stock Analysis page.